Clinical experience with fenticonazole 2% formulation in the treatment of dermatomycoses and pityriasis versicolor.

Abstract

Clinical efficacy of fenticonazole 2% cream has been tested on 30 patients with dermatomycoses and the 2% nebulized lotion on 10 patients with pityriasis versicolor. Treatment consisted of two topical applications of the drug for up to 5 weeks and clinical improvement and mycology were assessed at one-week intervals. Thirty-six patients (90%) were cured at the end of the 5-week period; 26 were cured from dermatomycoses and 10 from pityriasis versicolor. No recurrency/reinfection nor side-effects were encountered. The success attained by fenticonazole treatment indicates that it is a first choice drug in the therapy of superficial dermatomycoses.

• Authors: N Aste, M Pau, M Zucca, P Biggio
• Journal: International journal of clinical pharmacology research (Int J Clin Pharmacol Res) Vol. 7 Issue 6 Pg. 503-6 ( 1987) ISSN: 0251-1649 [Print] Switzerland
• PMID: 3440641 (Publication Type: Journal Article)

Chemical References

• Imidazoles
• Ointments
• fenticonazole

Topics

• Administration, Topical
• Adolescent
• Adult
• Aged
• Child
• Child, Preschool
• Dermatomycoses (drug therapy)
• Drug Evaluation
• Female
• Humans
• Imidazoles (administration & dosage, therapeutic use, toxicity)
• Male
• Middle Aged
• Ointments
• Tinea Versicolor (drug therapy)